Sun Finds US ‘Challenging’
Indian Company Sees Third-Quarter Profit Slide By 26%
Executive Summary
Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.